Mazagatos, ClaraMendioroz, JacoboRumayor-Zarzuelo, Mercedes BelénGallardo García, VirtudesÁlvarez Río, VirginiaCebollada Gracia, Ana DeliaBatalla Rebollo, NoaBarranco Boada, María IsabelPérez-Martínez, OlaiaLameiras Azevedo, Ana SofíaLópez González-Coviella, NievesCastrillejo, DanielFernández Ibáñez, AnaGiménez Duran, JaumeRamírez Córcoles, CristinaRamos Marín, VioletaLarrauri, AmparoMonge Corella, SusanaSARI Sentinel Surveillance RSV Study Group2024-06-262024-06-262024-05Influenza Other Respir Viruses. 2024 May;18(5):e13294.http://hdl.handle.net/20.500.12105/19872Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.engVoRhttp://creativecommons.org/licenses/by/4.0/SARIBurdenImpactRespiratory infectionsRespiratory syncitial virusSurveillanceRespiratory Syncytial Virus InfectionsHospitalizationAntiviral AgentsHumansSpainInfantIncidenceFemaleMaleRespiratory Syncytial Virus, HumanSentinel SurveillanceInfant, NewbornAntibodies, Monoclonal, HumanizedAtribución 4.0 Internacional38716791185e1329410.1111/irv.132941750-2659Influenza and other respiratory virusesopen access